John R. Stuelpnagel

CIK: 0001189140

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (71.4%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (28.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TXG

10x Genomics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

TXG
10x Genomics, Inc.
Sep 3, 2026
Sale(S)
Direct
6.8K shares at avg. $62.11$423K
TXG
10x Genomics, Inc.
Sep 3, 2026
Sale(S)
Direct
7K shares at avg. $60.66$425K
TXG
10x Genomics, Inc.
Sep 3, 2026
Sale(S)
Direct
6.2K shares at avg. $62.61$387K
TXG
10x Genomics, Inc.
Aug 11, 2026
Sale(S)
Direct
3K shares at avg. $58.73$176K
TXG
10x Genomics, Inc.
Aug 11, 2026
Sale(S)
Direct
17K shares at avg. $57.58$979K
TXG
10x Genomics, Inc.
Jun 4, 2026
Award(A)
Direct
8.8K shares-
TXG
10x Genomics, Inc.
Jun 3, 2025
Award(A)
Direct
15.4K shares-

		Type	Shares	Price		Ownership
Sep 3, 2026	TXG 10x Genomics, Inc.	Sale(S)	6,814	$62.11	$423,205	Direct
Sep 3, 2026	TXG 10x Genomics, Inc.	Sale(S)	7,012	$60.66	$425,333	Direct
Sep 3, 2026	TXG 10x Genomics, Inc.	Sale(S)	6,174	$62.61	$386,533	Direct
Aug 11, 2026	TXG 10x Genomics, Inc.	Sale(S)	3,000	$58.73	$176,175	Direct
Aug 11, 2026	TXG 10x Genomics, Inc.	Sale(S)	17,000	$57.58	$978,880	Direct
Jun 4, 2026	TXG 10x Genomics, Inc.	Award(A)	8,829	-	$0	Direct
Jun 3, 2025	TXG 10x Genomics, Inc.	Award(A)	15,357	-	-	Direct

1-7 of 7 transactions

About STUELPNAGEL JOHN R

STUELPNAGEL JOHN R (SEC CIK 0001189140) files insider reports with the SEC as Director of 10x Genomics, Inc. (TXG).

Signal8 holds 4 ownership filings by STUELPNAGEL JOHN R, all Form 4s, filed between Jun 5, 2025 and Sep 8, 2026. Those filings report 7 transactions, from Jun 3, 2025 to Sep 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on STUELPNAGEL JOHN R's filings is in PLEASANTON, CA.

Recent filings by STUELPNAGEL JOHN R

Sep 3, 2026: Open-market sales of TXG shares (3 lines, Form 4, code S).
Aug 11, 2026: Open-market sales of TXG shares (2 lines, Form 4, code S).
Jun 4, 2026: Grant or award of TXG shares (Form 4, code A).
Jun 3, 2025: Grant or award of TXG shares (Form 4, code A).

Other insiders filing for 10x Genomics, Inc. (TXG)

SULIMAN SHEHNAAZ, Director
Saxonov Serge, Chief Executive Officer
Taich Adam, Chief Financial Officer
Hindson Benjamin J.
Teichmann Sarah A., Director
Popovits Kimberly J, Director

How to read Form 4 transaction codes